Clinical trial · Interventional
Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer
Double-Blind, Vehicle-Controlled Study to Evaluate Apoptosis in Basal Cell Carcinoma Treated With Aldara™ (Imiquimod) Cream, 5% Applied Once or Twice a Day
NCT00079300CI-TRIAL-00010143completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Biological therapies, such as imiquimod cream, work in different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This randomized phase I trial is studying how well imiquimod cream works in treating patients with basal cell skin cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-melanomatous Skin Cancer | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| conventional surgery | Procedure | — | UNRESOLVED |
| imiquimod | Drug | Imiquimod | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed basal cell skin cancer * Superficial or nodular disease * No aggressive disease * At least 1 lesion at least 7 mm in diameter that meets the following criteria: * Primary tumor (no recurrent or previously treated disease) * Located on the scalp, face (including ears), trunk, or proximal extremities * Qualifies for surgical excision as primary therapy PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Not specified Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Not specified Renal * Not specified Cardiovascular * No evidence of a clinically significant or unstable medical condition that would adversely affect blood circulation Other * No dermatological disease (e.g., psoriasis or eczema) at the treatment site that may be exacerbated by treatment with imiquimod or interfere with examination * No febrile viral infection within the past 4 weeks * No evidence of a clinically significant or unstable medical condition that would adversely affect immune function PRIOR CONCURRENT THERAPY: Biologic therapy * More than 4 weeks since prior interferon, interferon inducers, or immunomodulators * No concurrent interferon, interferon inducers, or immunomodulators Chemotherapy * More than 6 months since prior anticancer chemotherapy * No concurrent anticancer chemotherapy Endocrine therapy * More than 4 weeks since prior oral or inhaled (more than 600 mcg/day for fluticasone or equivalent) corticosteroids * More than 4 weeks since prior topical steroids to the target tumor * Concurrent topical steroids in non-target areas are allowed provided amount used is ≤ 2 g of fluorinated steroids daily for \> 1 week or 6 g of beclomethasone for \> 1 week * No concurrent oral or inhaled corticosteroids Radiotherapy * Not specified Surgery * More than 4 months since prior biopsy Other * More than 4 weeks since prior immunosuppressive therapies * More than 4 weeks since prior cytotoxic or investigational drugs * No concurrent immunosuppressive therapies * No other concurrent cytotoxic or investigational drugs
References
Publications (0)
Data not yet available
No reference posted for this study.